Tech Company Financing Transactions
Proniras Funding Round
On 4/30/2018, Proniras landed funding from Alexandria Venture Investments, Arch Venture Partners and Johnson & Johnson Development Corporation.
Transaction Overview
Company Name
Announced On
4/30/2018
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2815 Eastlake Ave. E 300
Seattle, WA 98102
USA
Seattle, WA 98102
USA
Phone
Website
Email Address
Overview
Proniras is a specialty pharmaceutical company focused on the development of drugs for orphan neurological diseases with high unmet medical need. The Company's lead program is tezampanel, a novel AMPA/kainate receptor antagonist which antagonizes glutamate signaling in the central nervous system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Thong Le
Chief Operating Officer
David Schubert
Chief Scientific Officer
Christopher Toombs
VP - Finance
Lindsay Rayle
Browse more venture capital transactions:
Prev: 4/30/2018: Project SHIVOM venture capital transaction
Next: 4/30/2018: VisuWell venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs